Insider Buying: Cardiome Pharma Corp (COM) Insider Buys 10,000 Shares of Stock
Cardiome Pharma Corp (TSE:COM) (NASDAQ:CRME) insider Justin Renz acquired 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 24th. The shares were acquired at an average price of C$2.26 per share, for a total transaction of C$22,600.00.
Cardiome Pharma Corp (TSE:COM) traded up 2.83% during midday trading on Monday, reaching $2.91. 34,425 shares of the company traded hands. Cardiome Pharma Corp has a 12 month low of $2.63 and a 12 month high of $6.06. The firm’s 50 day moving average price is $5.11 and its 200 day moving average price is $4.72. The firm’s market capitalization is $98.36 million.
TRADEMARK VIOLATION WARNING: This report was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2017/08/28/insider-buying-cardiome-pharma-corp-com-insider-buys-10000-shares-of-stock.html.
Separately, HC Wainwright reiterated a “buy” rating on shares of Cardiome Pharma Corp in a research note on Wednesday, May 17th.
About Cardiome Pharma Corp
Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of patients suffering from heart diseases. It offers BRINAVESS (vernakalant (IV)) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and AGGRASTAT, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients.
Receive News & Stock Ratings for Cardiome Pharma Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma Corp and related stocks with our FREE daily email newsletter.